Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Nucleic Acids Res ; 44(6): 2661-76, 2016 Apr 07.
Article in English | MEDLINE | ID: mdl-26656492

ABSTRACT

Loss of 'Survival of Motor Neurons' (SMN) leads to spinal muscular atrophy (SMA), a disease characterized by degeneration of spinal cord alpha motor neurons, resulting in muscle weakness, paralysis and death during early childhood. SMN is required for assembly of the core splicing machinery, and splicing defects were documented in SMA. We previously uncovered that Coactivator-Associated Methyltransferase-1 (CARM1) is abnormally up-regulated in SMA, leading to mis-regulation of a number of transcriptional and alternative splicing events. We report here that CARM1 can promote decay of a premature terminating codon (PTC)-containing mRNA reporter, suggesting it can act as a mediator of nonsense-mediated mRNA decay (NMD). Interestingly, this pathway, while originally perceived as solely a surveillance mechanism preventing expression of potentially detrimental proteins, is now emerging as a highly regulated RNA decay pathway also acting on a subset of normal mRNAs. We further show that CARM1 associates with major NMD factor UPF1 and promotes its occupancy on PTC-containing transcripts. Finally, we identify a specific subset of NMD targets that are dependent on CARM1 for degradation and that are also misregulated in SMA, potentially adding exacerbated targeting of PTC-containing mRNAs to the already complex array of molecular defects associated with this disease.


Subject(s)
Motor Neurons/metabolism , Muscular Atrophy, Spinal/genetics , Nonsense Mediated mRNA Decay , Protein-Arginine N-Methyltransferases/genetics , RNA, Messenger/genetics , Trans-Activators/genetics , Alternative Splicing , Animals , Cell Line , Codon, Terminator , Exons , Humans , Introns , Mice , Mice, Inbred C57BL , Motor Neurons/pathology , Muscular Atrophy, Spinal/metabolism , Muscular Atrophy, Spinal/pathology , Protein-Arginine N-Methyltransferases/metabolism , RNA Helicases , RNA, Messenger/metabolism , Spinal Cord/metabolism , Spinal Cord/pathology , Trans-Activators/metabolism
2.
Hum Mol Genet ; 20(3): 553-79, 2011 Feb 01.
Article in English | MEDLINE | ID: mdl-21088113

ABSTRACT

Spinal muscular atrophy is an autosomal-recessive neuromuscular disease caused by disruption of the survival of motor neuron (SMN) gene, which promotes cytoplasmic assembly of the splicing core machinery. It remains unclear how a deficiency in SMN results in a disorder leading to selective degeneration of lower motor neurons. We report here that SMN interacts with RNA-binding protein HuD in neurites of motorneuron-derived MN-1 cells. This interaction is mediated through the Tudor domain of SMN and, importantly, naturally occurring Tudor mutations found in patients with severe spinal muscular atrophy (SMA) completely abrogate the interaction, underscoring its relevance to the disease process. We also characterized a regulatory pathway involving coactivator-associated arginine methyltransferase 1 (CARM1) and HuD. Specifically, we show that CARM1 expression is rapidly downregulated, at the protein level, following induction of differentiation through retinoid and neurotrophic signaling. Using purified proteins, we demonstrate that methylation of HuD by CARM1 reduces its interaction with the p21(cip1/waf1) mRNA, showing that CARM1 can directly influence RNA-binding activity. We further demonstrate that this CARM1-dependent regulatory switch mainly controls the activity of HuD in promoting cell-cycle exit, whereas the interaction between HuD and SMN is required for proper recruitment of HuD and its mRNA targets in neuronal RNA granules. Finally, we were able to rescue SMA-like defects in a hypomorphic Smn knockdown MN-1 cell line through overexpression of HuD. Together, these findings extend our understanding of specific role(s) of SMN in motor neurons and provide crucial insights into potential new avenues for SMA therapeutic strategies.


Subject(s)
ELAV Proteins/metabolism , Muscular Atrophy, Spinal/metabolism , Neurites/metabolism , Survival of Motor Neuron 1 Protein/metabolism , Animals , Base Sequence , Cell Cycle , Cell Cycle Proteins/genetics , Cell Line , ELAV-Like Protein 4 , Fluorescent Antibody Technique , Gene Expression , Gene Knockdown Techniques , Immunoblotting , Methylation , Mice , Muscular Atrophy, Spinal/genetics , Mutation , Nerve Growth Factors , Phenotype , Polymerase Chain Reaction , Protein Interaction Domains and Motifs , Protein-Arginine N-Methyltransferases/genetics , Protein-Arginine N-Methyltransferases/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Small Interfering , Retinol-Binding Proteins , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL
...